Eugene A. Zhukovsky
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells.
Journal: Nature cancer
Published: October 09, 2023
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.
Journal: Nature communications
Published: July 31, 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Journal: Frontiers in immunology
Published: February 17, 2023
DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Journal: Journal for immunotherapy of cancer
Published: October 11, 2021
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: May 16, 2019
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.
Journal: Frontiers in oncology
Published: February 01, 2017
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
Journal: Protein engineering, design & selection : PEDS
Published: December 28, 2016
Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2016
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
Journal: Current opinion in immunology
Published: January 08, 2016
Last Updated: 09/26/2026